Literatur
-
1
Cornberg M, Protzer U, Dollinger M M et al.
Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021 / 011.
Z Gastroenterol.
2007;
45
525-574
-
2 World Health Organization (WHO) .Hepatitis B. 2008
-
3
Robert Koch-Institut .
Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2009.
Epidemiologisches Bulletin.
2010;
20
177-190
-
4
Perz J F, Armstrong G L, Farrington L A et al.
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
J Hepatol.
2006;
45
529-538
-
5
Lavanchy D.
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.
J Viral Hepat.
2004;
11
97-107
-
6
Rehermann B, Nascimbeni M.
Immunology of hepatitis B virus and hepatitis C virus infection.
Nat Rev Immunol.
2005;
5
215-229
-
7
Ganem D, Prince A M.
Hepatitis B virus infection – natural history and clinical consequences.
N Engl J Med.
2004;
350
1118-1129
-
8
Chen C J, Yang H I, Su J et al.
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA.
2006;
295
65-73
-
9
Chen G, Lin W, Shen F et al.
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study.
Am J Gastroenterol.
2006;
101
1797-1803
-
10
Iloeje U H, Yang H I, Su J et al.
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
Gastroenterology.
2006;
130
678-686
-
11
Yang H I, Sherman M, Su J et al.
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
J Clin Oncol.
2010;
28
2437-2444
-
12
McMahon B J, Alward W L, Hall D B et al.
Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.
J Infect Dis.
1985;
151
599-603
-
13
Simonetti J, Bulkow L, McMahon B J et al.
Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus.
Hepatology.
2010;
51
1531-1537
-
14
Knoll A, Hartmann A, Hamoshi H et al.
Serological pattern „anti-HBc alone”: characterization of 552 individuals and clinical significance.
World J Gastroenterol.
2006;
12
1255-1260
-
15
Grob P, Jilg W, Bornhak H et al.
Serological pattern „anti-HBc alone”: report on a workshop.
J Med Virol.
2000;
62
450-455
-
16
Berger A, Doerr H W, Rabenau H F et al.
High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen.
Intervirology.
2000;
43
71-76
-
17
Jilg W, Hottentrager B, Weinberger K et al.
Prevalence of markers of hepatitis B in the adult German population.
J Med Virol.
2001;
63
96-102
-
18
Wedemeyer H, Cornberg M, Tegtmeyer B et al.
Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication.
Clin Microbiol Infect.
2004;
10
70-72
-
19
Stramer S L, Wend U, Candotti D et al.
Nucleic acid testing to detect HBV infection in blood donors.
N Engl J Med.
2011;
364
236-247
-
20
Chakvetadze C, Roussin C, Roux J et al.
Efficacy of hepatitis B sero-vaccination in newborns of African HBsAg positive mothers.
Vaccine.
2011;
29
2846-2849
-
21
Gerlich W H, Bremer C, Saniewski M et al.
Occult hepatitis B virus infection: detection and significance.
Dig Dis.
2010;
28
116-125
-
22
Raimondo G, Pollicino T, Cacciola I et al.
Occult hepatitis B virus infection.
J Hepatol.
2007;
46
160-170
-
23
Torbenson M, Thomas D L.
Occult hepatitis B.
Lancet Infect Dis.
2002;
2
479-486
-
24
Rizzetto M.
Hepatitis delta: the virus and the disease.
J Hepatol.
1990;
11 (Suppl 1)
S145-S148
-
25
Wedemeyer H, Manns M P.
Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.
Nat Rev Gastroenterol Hepatol.
2010;
7
31-40
-
26
McMahon B J.
Natural history of chronic hepatitis B.
Clin Liver Dis.
2010;
14
381-396
-
27
Veldhuijzen I K, Toy M, Hahne S J et al.
Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
Gastroenterology.
2010;
138
522-530
-
28
Williams R.
Global challenges in liver disease.
Hepatology.
2006;
44
521-526
-
29
Wursthorn K, Wedemeyer H, Manns M P.
Managing HBV in patients with impaired immunity.
Gut.
2010;
59
1430-1445
-
30
Walz A, Wirth S, Hucke J et al.
Vertical transmission of hepatitis B virus (HBV) from mothers negative for HBV surface antigen and positive for antibody to HBV core antigen.
J Infect Dis.
2009;
200
1227-1231
-
31
Robert Koch-Institut .
Mitteilung der Ständigen Impfkommission am Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2010.
Epidemiologisches Bulletin.
2010;
30
279-298
-
32
Pramoolsinsap C, Poovorawan Y, Hirsch P et al.
Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV.
Ann Trop Med Parasitol.
1999;
93
745-751
-
33
Palmer D R, Perry K R, Mortimer P P et al.
Variation in the sensitivity of HBsAg screening kits.
Transfus Med.
1996;
6
311-317
-
34
Weber B.
Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact.
J Clin Virol.
2005;
32
102-112
-
35
Scheiblauer H, Soboll H, Nick S.
Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection.
J Med Virol.
2006;
78 (Suppl 1)
S66-S70
-
36
Westhoff T H, Jochimsen F, Schmittel A et al.
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.
Blood.
2003;
102
1930
-
37
Awerkiew S, Daumer M, Reiser M et al.
Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient.
J Clin Virol.
2007;
38
83-86
-
38
Werle-Lapostolle B, Bowden S, Locarnini S et al.
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.
Gastroenterology.
2004;
126
1750-1758
-
39
Schuttler C G, Wend U C, Faupel F M et al.
Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg).
J Clin Virol.
2010;
47
238-242
-
40
Sonneveld M J, Rijckborst V, Boucher C A et al.
Prediction of sustained response to peg-interferon alpha-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
Hepatology.
2010;
52
1251-1257
-
41
Brunetto M R, Moriconi F, Bonino F et al.
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alpha-2a in HBeAg-negative chronic hepatitis B.
Hepatology.
2009;
49
1141-1150
-
42
Moucari R, Mackiewicz V, Lada O et al.
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alpha-2a in HBeAg-negative patients.
Hepatology.
2009;
49
1151-1157
-
43
Rijckborst V, Hansen B E, Cakaloglu Y et al.
Early on-treatment prediction of response to peginterferon alpha-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Hepatology.
2010;
52
454-461
-
44
Wiegand J, Wedemeyer H, Finger A et al.
A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
Antivir Ther.
2008;
13
547-554
-
45
Borgniet O, Parvaz P, Bouix C et al.
Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B.
J Med Virol.
2009;
81
1336-1342
-
46
Wursthorn K, Jung M, Riva A et al.
Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.
Hepatology.
2010;
52
1611-1620
-
47
Rodella A, Galli C, Terlenghi L et al.
Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B.
J Clin Virol.
2006;
37
206-212
-
48
Jaroszewicz J, Calle Serrano B, Wursthorn K et al.
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.
J Hepatol.
2010;
52
514-522
-
49
Nguyen T, Thompson A J, Bowden S et al.
Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia.
J Hepatol.
2010;
52
508-513
-
50
Thompson A J, Nguyen T, Iser D et al.
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
Hepatology.
2010;
51
1933-1944
-
51
Brunetto M R, Oliveri F, Colombatto P et al.
Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.
Gastroenterology.
2010;
139
483-490
-
52
Colloredo G, Bellati G, Leandro G et al.
Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new „gray-zone” for the evaluation of „borderline” values.
J Hepatol.
1996;
25
644-648
-
53
Colloredo Mels G, Bellati G, Leandro G et al.
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations.
Arch Virol Suppl.
1993;
8
203-211
-
54
Baylis S A, Heath A B, Chudy M et al.
An international collaborative study to establish the 2nd World Health Organization International Standard for hepatitis B virus DNA nucleic acid amplification technology-based assays.
Vox Sang.
2008;
94
358-362
-
55
Heermann K H, Gerlich W H, Chudy M et al.
Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group.
J Clin Microbiol.
1999;
37
68-73
-
56
Yang H I, Lu S N, Liaw Y F et al.
Hepatitis B e antigen and the risk of hepatocellular carcinoma.
N Engl J Med.
2002;
347
168-174
-
57
Wedemeyer H, Heidrich B, Manns M P.
Hepatitis D virus infection – not a vanishing disease in Europe!.
Hepatology.
2007;
45
1331-1332
; author reply 1332 – 1333
-
58
Shattock A G, Morris M C.
Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies.
J Clin Microbiol.
1991;
29
1873-1876
-
59
Tang J R, Cova L, Lamelin J P et al.
Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction.
J Hepatol.
1994;
21
953-960
-
60
Mederacke I, Bremer B, Heidrich B et al.
Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics.
J Clin Microbiol.
2010;
48
2022-2029
-
61
Castelnau C, Le Gal F, Ripault M P et al.
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Hepatology.
2006;
44
728-735
-
62
Le Gal F, Gordien E, Affolabi D et al.
Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients.
J Clin Microbiol.
2005;
43
2363-2369
-
63
Lau J Y, Smith H M, Chaggar K et al.
Significance of IgM anti-hepatitis D virus (HDV) in chronic HDV infection.
J Med Virol.
1991;
33
273-276
-
64
Wedemeyer H, Yurdaydin C, Dalekos G N et al.
Peginterferon plus adefovir versus either drug alone for hepatitis delta.
N Engl J Med.
2011;
364
322-331
-
65
Yuen M F, Tanaka Y, Fong D Y et al.
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.
J Hepatol.
2009;
50
80-88
-
66
Lok A S, McMahon B J.
Chronic hepatitis B: update 2009.
Hepatology.
2009;
50
661-662
-
67
Sherman M, Peltekian K M, Lee C.
Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.
Hepatology.
1995;
22
432-438
-
68
Yang B, Zhang B, Xu Y et al.
Prospective study of early detection for primary liver cancer.
J Cancer Res Clin Oncol.
1997;
123
357-360
-
69
Schirmacher P, Fleig W E, Dienes H P.
[Biopsy diagnosis of chronic hepatitis].
Z Gastroenterol.
2004;
42
175-185
-
70
Nair V, Fischer S E, Adeyi O A.
Non-viral-related pathologic findings in liver needle biopsy specimens from patients with chronic viral hepatitis.
Am J Clin Pathol.
2010;
133
127-132
-
71
Marcellin P, Ziol M, Bedossa P et al.
Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B.
Liver Int.
2009;
29
242-247
-
72
Coco B, Oliveri F, Maina A M et al.
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.
J Viral Hepat.
2007;
14
360-369
-
73
Kim S U, Seo Y S, Cheong J Y et al.
Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B.
Aliment Pharmacol Ther.
2010;
32
498-505
-
74 Gerlich W H, Thomssen R, Bircher J. et al .Terminology, structure and laboratory diagnosis of hepatitis viruses. In: Gerlich W H, Thomssen R, Bircher J, (eds) Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press; 1999: 828-869
-
75
Wai C T, Chu C J, Hussain M et al.
HBV genotype B is associated with better response to interferon therapy in HBeAg(+ ) chronic hepatitis than genotype C.
Hepatology.
2002;
36
1425-1430
-
76
Janssen H L, Zonneveld van M, Senturk H et al.
Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Lancet.
2005;
365
123-129
-
77
Wiegand J, Hasenclever D, Tillmann H L.
Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence.
Antivir Ther.
2008;
13
211-220
-
78
Erhardt A, Blondin D, Hauck K et al.
Response to interferon alpha is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.
Gut.
2005;
54
1009-1013
-
79
Flink H J, Zonneveld van M, Hansen B E et al.
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Am J Gastroenterol.
2006;
101
297-303
-
80
Zoulim F, Locarnini S.
Hepatitis B virus resistance to nucleos(t)ide analogues.
Gastroenterology.
2009;
137
1593-1608
-
81
Schildgen O, Sirma H, Funk A et al.
Variant of hepatitis B virus with primary resistance to adefovir.
N Engl J Med.
2006;
354
1807-1812
-
82
Tassopoulos N C, Papaevangelou G J, Sjogren M H et al.
Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults.
Gastroenterology.
1987;
92
1844-1850
-
83
Kumar M, Satapathy S, Monga R et al.
A randomized controlled trial of lamivudine to treat acute hepatitis B.
Hepatology.
2007;
45
97-101
-
84
Yu J W, Sun L J, Zhao Y H et al.
The study of efficacy of lamivudine in patients with severe acute hepatitis B.
Dig Dis Sci.
2010;
55
775-783
-
85
Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E et al.
Lamivudine treatment for acute severe hepatitis B: a pilot study.
Liver Int.
2004;
24
547-551
-
86
Tillmann H L, Hadem J, Leifeld L et al.
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
J Viral Hepat.
2006;
13
256-263
-
87
Brunetto M R, Oliveri F, Coco B et al.
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.
J Hepatol.
2002;
36
263-270
-
88
Kumar M, Sarin S K, Hissar S et al.
Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.
Gastroenterology.
2008;
134
1376-1384
-
89
Lai M, Hyatt B J, Nasser I et al.
The clinical significance of persistently normal ALT in chronic hepatitis B infection.
J Hepatol.
2007;
47
760-767
-
90
Tsang P S, Trinh H, Garcia R T et al.
Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels.
Clin Gastroenterol Hepatol.
2008;
6
569-574
-
91
Papatheodoridis G V, Manesis E K, Manolakopoulos S et al.
Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?.
Hepatology.
2008;
48
1451-1459
-
92
Wu I C, Lai C L, Han S H et al.
Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
Hepatology.
2010;
51
1185-1189
-
93
Manno M, Camma C, Schepis F et al.
Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.
Gastroenterology.
2004;
127
756-763
-
94
Chen J D, Yang H I, Iloeje U H et al.
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.
Gastroenterology.
2010;
138
1747-1754
-
95
Kumagai K, Takagi T, Nakamura S et al.
Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan.
Ann Oncol.
1997;
8 (Suppl 1)
107-109
-
96
Lok A S, Liang R H, Chiu E K et al.
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.
Gastroenterology.
1991;
100
182-188
-
97
Markovic S, Drozina G, Vovk M et al.
Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.
Hepatogastroenterology.
1999;
46
2925-2930
-
98
Nakamura Y, Motokura T, Fujita A et al.
Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987 – 1991.
Cancer.
1996;
78
2210-2215
-
99
Yeo W, Chan P K, Zhong S et al.
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
J Med Virol.
2000;
62
299-307
-
100
Aomatsu T, Komatsu H, Yoden A et al.
Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin"s lymphoma in an HBV carrier.
Eur J Pediatr.
2010;
169
167-171
-
101
Chen P M, Chiou T J, Fan F S et al.
Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation.
Transplantation.
1999;
67
1425-1433
-
102
Lau G K, Liang R, Chiu E K et al.
Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.
Bone Marrow Transplant.
1997;
19
795-799
-
103
Dervite I, Hober D, Morel P.
Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.
N Engl J Med.
2001;
344
68-69
-
104
Hui C K, Cheung W W, Zhang H Y et al.
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
Gastroenterology.
2006;
131
59-68
-
105
Stange M A, Tutarel O, Pischke S et al.
Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.
Z Gastroenterol.
2010;
48
258-263
-
106
Zingarelli S, Frassi M, Bazzani C et al.
Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
J Rheumatol.
2009;
36
1188-1194
-
107
Yagci M, Ozkurt Z N, Yegin Z A et al.
Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.
Hematology.
2010;
15
240-244
-
108
Lau G K, Yiu H H, Fong D Y et al.
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.
Gastroenterology.
2003;
125
1742-1749
-
109
Katz L H, Fraser A, Gafter-Gvili A et al.
Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.
J Viral Hepat.
2008;
15
89-102
-
110
Martyak L A, Taqavi E, Saab S.
Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis.
Liver Int.
2008;
28
28-38
-
111
Manns M P, Wedemeyer H, Cornberg M.
Treating viral hepatitis C: efficacy, side effects, and complications.
Gut.
2006;
55
1350-1359
-
112
Craxi A, Di Bona D, Camma C.
Interferon-alpha for HBeAg-positive chronic hepatitis B.
J Hepatol.
2003;
39 (Suppl 1)
S99-S105
-
113
Di Marco V, Marzano A, Lampertico P et al.
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
Hepatology.
2004;
40
883-891
-
114
Liaw Y F, Sung J J, Chow W C et al.
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
N Engl J Med.
2004;
351
1521-1531
-
115
Zeuzem S, Gane E, Liaw Y F et al.
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.
J Hepatol.
2009;
51
11-20
-
116
Yuen M F, Fong D Y, Wong D K et al.
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response.
Hepatology.
2007;
46
1695-1703
-
117
Liaw Y F, Gane E, Leung N et al.
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Gastroenterology.
2009;
136
486-495
-
118
Ha N B, Ha N B, Garcia R T et al.
Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil.
Hepatology.
2009;
50
727-734
-
119
Chan H L, Tang J L, Tam W et al.
The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis.
Aliment Pharmacol Ther.
2001;
15
1899-1905
-
120
Mutchnick M G, Lindsay K L, Schiff E R et al.
Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.
J Viral Hepat.
1999;
6
397-403
-
121
Yang Y F, Zhao W, Zhong Y D et al.
Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.
Antiviral Res.
2008;
77
136-141
-
122
Zavaglia C, Severini R, Tinelli C et al.
A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.
Dig Dis Sci.
2000;
45
690-696
-
123
Cotonat T, Quiroga J A, Lopez-Alcorocho J M et al.
Pilot study of combination therapy with ribavirin and interferon alpha for the retreatment of chronic hepatitis B e antibody-positive patients.
Hepatology.
2000;
31
502-506
-
124
Rijckborst V, ter Borg M J, Cakaloglu Y et al.
A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.
Am J Gastroenterol.
2010;
105
1762-1769
-
125
Dahmen A, Herzog-Hauff S, Bocher W O et al.
Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.
J Med Virol.
2002;
66
452-460
-
126
Michel M L, Mancini-Bourgine M.
Therapeutic vaccination against chronic hepatitis B virus infection.
J Clin Virol.
2005;
34 (Suppl 1)
S108-S114
-
127
Vandepapeliere P, Lau G K, Leroux-Roels G et al.
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
Vaccine.
2007;
25
8585-8597
-
128
Heintges T, Petry W, Kaldewey M et al.
Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B.
Dig Dis Sci.
2001;
46
901-906
-
129
Cohard M, Poynard T, Mathurin P et al.
Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis.
Hepatology.
1994;
20
1390-1398
-
130
Brook M G, Chan G, Yap I et al.
Randomised controlled trial of lymphoblastoid interferon alpha in Europid men with chronic hepatitis B virus infection.
BMJ.
1989;
299
652-656
-
131
Fattovich G, Brollo L, Boscaro S et al.
Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B.
J Hepatol.
1989;
9
331-337
-
132
Niederau C, Heintges T, Lange S et al.
Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B.
N Engl J Med.
1996;
334
1422-1427
-
133
Papatheodoridis G V, Manesis E, Hadziyannis S J.
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.
J Hepatol.
2001;
34
306-313
-
134
Lin S M, Yu M L, Lee C M et al.
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.
J Hepatol.
2007;
46
45-52
-
135
Cooksley W G, Piratvisuth T, Lee S D et al.
Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.
J Viral Hepat.
2003;
10
298-305
-
136
Chan H L, Hui A Y, Wong V W et al.
Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.
Hepatology.
2005;
41
1357-1364
-
137
Lau G K, Piratvisuth T, Luo K X et al.
Peginterferon Alpha-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2005;
352
2682-2695
-
138
Buster E H, Flink H J, Cakaloglu Y et al.
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peg-interferon alpha-2b.
Gastroenterology.
2008;
135
459-467
-
139
Liaw Y F, Xie Q, Han K et al.
Shorter Duration and Lower Dose of Peginterferon Alpha-2a Therapy Results in Inferior Hbeag Seroconversion Rates Compared with the Duration and Dose of 48 Weeks and 180 µg: NEPTUNE Study.
Hepatology.
2010;
52
429A
-
140
Gish R G, Lau D T, Schmid P et al.
A pilot study of extended duration peginterferon alpha-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Am J Gastroenterol.
2007;
102
2718-2723
-
141
Manesis E K, Hadziyannis S J.
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.
Gastroenterology.
2001;
121
101-109
-
142
Lampertico P, Vigano M, Colombo M et al.
Extended (2 years) treatment with peg-interferon alpha-2A [40kd] improves sustained response rates in Genotype D-Patients with HBEAG negative chronic hepatitis B.
J Hepatol.
2010;
52
S45
-
143
Fattovich G, Giustina G, Sanchez-Tapias J et al.
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP).
Am J Gastroenterol.
1998;
93
896-900
-
144
Marcellin P, Bonino F, Lau G K et al.
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peg-interferon alpha-2a.
Gastroenterology.
2009;
136
2169-2179.e1 – 4
-
145
Moucari R, Korevaar A, Lada O et al.
High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
J Hepatol.
2009;
50
1084-1092
-
146
Poynard T, Massard J, Rudler M et al.
Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials.
Gastroenterol Clin Biol.
2009;
33
916-922
-
147
Wong V W, Wong G L, Yan K K et al.
Durability of peginterferon alpha-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Hepatology.
2010;
51
1945-1953
-
148
Buster E H, Hansen B E, Lau G K et al.
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alpha.
Gastroenterology.
2009;
137
2002-2009
-
149
Buster E H, Hansen B E, Buti M et al.
Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.
Hepatology.
2007;
46
388-394
-
150
Buster E H, Flink H J, Simsek H et al.
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
Am J Gastroenterol.
2009;
104
2449-2457
-
151
Fried M W, Piratvisuth T, Lau G K et al.
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peg-interferon alpha-2a for HBeAg-positive chronic hepatitis B.
Hepatology.
2008;
47
428-434
-
152
Lau G KK, Marcellin P, Brunetto M et al.
On-Treatment Monitoring of HBsAg levels to predict response to peg-interferon alpha-2a in patients with HbeAg-positive chronic hepatitis B.
J Hepatol.
2009;
50
S333
-
153
Piratvisuth T, Marcellin P.
Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all HBeAg-positive patients.
Hepatology.
2011;
; in press
-
154
Bonino F, Marcellin P, Lau G K et al.
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
Gut.
2007;
56
699-705
-
155
Marcellin P, Lau G K, Bonino F et al.
Peg-interferon alpha-2a alone, lamivudine alone, the two in combination in patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2004;
351
1206-1217
-
156
Hui A Y, Chan H L, Cheung A Y et al.
Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon.
Aliment Pharmacol Ther.
2005;
22
519-528
-
157
Kaymakoglu S, Oguz D, Gur G et al.
Pegylated interferon Alpha-2b monotherapy and pegylated interferon Alpha-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
Antimicrob Agents Chemother.
2007;
51
3020-3022
-
158
Piccolo P, Lenci I, Demelia L et al.
A randomized controlled trial of pegylated interferon-alpha-2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Antivir Ther.
2009;
14
1165-1174
-
159
Vassiliadis T, Tziomalos K, Patsiaoura K et al.
Lamivudine/pegylated interferon alpha-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B.
J Gastroenterol Hepatol.
2007;
22
1582-1588
-
160
Wursthorn K, Lutgehetmann M, Dandri M et al.
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Hepatology.
2006;
44
675-684
-
161
Marcellin P, Avila C, Wursthorn K et al.
telbivudine (ldt) plus peg-interferon (PEGIFN) in hbeag-positive chronic hepatitis b – very potent antiviral efficacy but risk of peripheral neuropathy (PN).
J Hepatol.
2010;
52
S6-S7
-
162
Flink H J, Sprengers D, Hansen B E et al.
Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.
Gut.
2005;
54
1604-1609
-
163
Bommel van F, Man R A, Wedemeyer de H et al.
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
Hepatology.
2010;
51
73-80
-
164
Berg T, Marcellin P, Zoulim F et al.
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Gastroenterology.
2010;
139
1207-1217
-
165
Lai C L, Chien R N, Leung N W et al.
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
N Engl J Med.
1998;
339
61-68
-
166
Dienstag J L, Schiff E R, Wright T L et al.
Lamivudine as initial treatment for chronic hepatitis B in the United States.
N Engl J Med.
1999;
341
1256-1263
-
167
Liaw Y F, Leung N W, Chang T T et al.
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Gastroenterology.
2000;
119
172-180
-
168
Chang T T, Gish R G, Man de R et al.
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2006;
354
1001-1010
-
169
Yuen M F, Seto W K, Chow D H et al.
Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
Antivir Ther.
2007;
12
1295-1303
-
170
Lai C L, Gane E, Liaw Y F et al.
Telbivudine versus lamivudine in patients with chronic hepatitis B.
N Engl J Med.
2007;
357
2576-2588
-
171
Hashimoto Y, Suzuki F, Hirakawa M et al.
Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
J Med Virol.
2010;
82
684-691
-
172
Hadziyannis S J, Tassopoulos N C, Heathcote E J et al.
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
N Engl J Med.
2003;
348
800-807
-
173
Marcellin P, Chang T T, Lim S G et al.
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
N Engl J Med.
2003;
348
808-816
-
174
Hadziyannis S J, Tassopoulos N C, Heathcote E J et al.
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Gastroenterology.
2006;
131
1743-1751
-
175
Marcellin P, Heathcote E J, Buti M et al.
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
N Engl J Med.
2008;
359
2442-2455
-
176
Lee J M, Park J Y, Kim do Y et al.
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Antivir Ther.
2010;
15
235-241
-
177
Lai C L, Shouval D, Lok A S et al.
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2006;
354
1011-1020
-
178
Tenney D J, Rose R E, Baldick C J et al.
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy.
Hepatology.
2009;
49
1503-1514
-
179
Chang T T, Chao Y C, Gorbakov V V et al.
Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B.
J Viral Hepat.
2009;
16
784-789
-
180
Reijnders J G, Deterding K, Petersen J et al.
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
J Hepatol.
2010;
52
493-500
-
181
Chang T T, Lai C L, Kew Yoon S et al.
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Hepatology.
2010;
51
422-430
-
182
Lampertico P, Vigano M, Facchetti F et al.
effectiveness of entecavir for nuc-naive, HBEAG-negative chronic hepatitis B patients in clinical practice: A 2-year multicenter cohort study in 311 patients.
J Hepatol.
2010;
52
S389-S390
-
183
Lai C L, Leung N, Teo E K et al.
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
Gastroenterology.
2005;
129
528-536
-
184
Heathcote E J, Marcellin P, Buti M et al.
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Gastroenterology.
2011;
140
132-143
-
185
Westland C, Delaney W T, Yang H et al.
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.
Gastroenterology.
2003;
125
107-116
-
186
Perrillo R P, Lai C L, Liaw Y F et al.
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Hepatology.
2002;
36
186-194
-
187
Chien R N, Yeh C T, Tsai S L et al.
Determinants for sustained HBeAg response to lamivudine therapy.
Hepatology.
2003;
38
1267-1273
-
188
Peters M G, Hann Hw H, Martin P et al.
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Gastroenterology.
2004;
126
91-101
-
189
Sung J J, Lai J Y, Zeuzem S et al.
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
J Hepatol.
2008;
48
728-735
-
190
Lampertico P, Vigano M, Manenti E et al.
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
Hepatology.
2005;
42
1414-1419
-
191
Locarnini S, Hatzakis A, Heathcote J et al.
Management of antiviral resistance in patients with chronic hepatitis B.
Antivir Ther.
2004;
9
679-693
-
192
Bommel van F, Wunsche T, Mauss S et al.
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Hepatology.
2004;
40
1421-1425
-
193
Bommel van F, Zollner B, Sarrazin C et al.
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
Hepatology.
2006;
44
318-325
-
194
Lampertico P, Vigano M, Manenti E et al.
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
Gastroenterology.
2007;
133
1445-1451
-
195
Lok A S, Zoulim F, Locarnini S et al.
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.
Hepatology.
2007;
46
254-265
-
196
Tillmann H L, McHutchison J G.
Telbivudine versus lamivudine in patients with chronic hepatitis B.
N Engl J Med.
2008;
358
1517
; author reply 1517; author reply 1518
-
197
Patterson S J, George J, Strasser S I et al.
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
Gut.
2011;
60
247-254
-
198
Deterding K, Manns M P, Wedemeyer H.
Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?.
J Hepatol.
2008;
49
862-863
-
199
Vries-Sluijs T E, Reijnders J G, Hansen B E et al.
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
Gastroenterology.
2010;
139
1934-1941
-
200
Tamori de A, Enomoto M, Kobayashi S et al.
Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus.
J Viral Hepat.
2010;
17
123-129
-
201
Bommel van F, Man R A, Wedemeyer de H et al.
Renal safety and antiviral efficacy of tenofovir disoproxil fumarate (TDF) monotherapy in nucleos(t)ide analogue refractory patients with hepatitis B virus (HBV) mono-infection.
J Hepatol.
2010;
52
S398
-
202
Izzedine H, Hulot J S, Vittecoq D et al.
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Nephrol Dial Transplant.
2005;
20
743-746
-
203
Karras A, Lafaurie M, Furco A et al.
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.
Clin Infect Dis.
2003;
36
1070-1073
-
204
Rodriguez-Novoa S, Alvarez E, Labarga P et al.
Renal toxicity associated with tenofovir use.
Expert Opin Drug Saf.
2010;
9
545-559
-
205
Manns M, Akarca U S, Chang T T et al.
Low rates of nucleos(t)ide-associated adverse events in the long-term experience with entecavir.
J Hepatol.
2010;
52
S393
-
206
Yuan J M, Govindarajan S, Arakawa K et al.
Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.
Cancer.
2004;
101
1009-1017
-
207
Wang C S, Yao W J, Chang T T et al.
The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses.
Cancer Epidemiol Biomarkers Prev.
2009;
18
2054-2060
-
208
Cheng A Y, Kong A P, Wong V W et al.
Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients.
Diabetologia.
2006;
49
1777-1784
-
209
Diamond T, Stiel D, Lunzer M et al.
Osteoporosis and skeletal fractures in chronic liver disease.
Gut.
1990;
31
82-87
-
210
Zoulim F.
New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.
J Hepatol.
2005;
42
302-308
-
211
Wursthorn K, Buggisch P, Lutgehetmann M et al.
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
Antivir Ther.
2006;
11
647-652
-
212
Dienstag J L, Cianciara J, Karayalcin S et al.
Durability of serologic response after lamivudine treatment of chronic hepatitis B.
Hepatology.
2003;
37
748-755
-
213
Gish R G, Lok A S, Chang T T et al.
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gastroenterology.
2007;
133
1437-1444
-
214
Ryu S H, Chung Y H, Choi M H et al.
Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.
J Hepatol.
2003;
39
614-619
-
215
Lee H W, Lee H J, Hwang J S et al.
Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.
Hepatology.
2010;
51
415-421
-
216
Song B C, Suh D J, Lee H C et al.
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
Hepatology.
2000;
32
803-806
-
217
Nunen A B, Hansen B E, Suh D J et al.
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
Gut.
2003;
52
420-424
-
218
Reijnders J G, Perquin M J, Zhang van N et al.
Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Gastroenterology.
2010;
139
491-498
-
219
Shouval D, Lai C L, Chang T T et al.
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
J Hepatol.
2009;
50
289-295
-
220
Hadziyannis S J, Sevastianos V, Rapti I N et al.
Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B.
Hepatology.
2006;
44
231A-232A
-
221
Papatheodoridis G V, Lampertico P, Manolakopoulos S et al.
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
J Hepatol.
2010;
53
348-356
-
222
Liaw Y F, Sheen I S, Lee C M et al.
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Hepatology.
2011;
53
62-72
-
223
Shim J H, Lee H C, Kim K M et al.
Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis.
J Hepatol.
2010;
52
176-182
-
224
Villeneuve J P, Condreay L D, Willems B et al.
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
Hepatology.
2000;
31
207-210
-
225
Gane E J, Chan H L, Choudhuri G et al.
Treatment of decompesated hbv-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine.
J Hepatol.
2010;
52
S4
-
226
Petersen J, Lutgehetmann M, Zoulim F et al.
Safety and efficacy of entecavir and tenofovir combination-therapy in hepatitis B patients with previous treatment failures. an international multicenter cohort study.
J Hepatol.
2010;
52
S394-S395
-
227
Liaw Y F, Raptopoulou-Gigi M, Cheinquer H et al.
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation.
Hepatology.
2009;
50
505A
-
228
Lange C M, Bojunga J, Hofmann W P et al.
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.
Hepatology.
2009;
50
2001-2006
-
229
Conca P, Riccio A, Tarantino G.
Successful lamivudine monotherapy in an elderly patient suffering from HBV-related decompensated cirrhosis associated with widespread leukocytoclastic vasculitis.
Int J Immunopathol Pharmacol.
2009;
22
531-535
-
230
Erhardt A, Sagir A, Guillevin L et al.
Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine.
J Hepatol.
2000;
33
677-683
-
231
Gan S I, Devlin S M, Scott-Douglas N W et al.
Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection.
Can J Gastroenterol.
2005;
19
625-629
-
232
Kanaan N, Horsmans Y, Goffin E.
Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection.
Clin Nephrol.
2006;
65
208-210
-
233
Kruger M, Boker K H, Zeidler H et al.
Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alpha-2b.
J Hepatol.
1997;
26
935-939
-
234
Wen Y K, Chen M L.
Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy.
Clin Nephrol.
2006;
65
211-215
-
235
Fabrizi F, Messa P, Martin P.
Hepatitis B virus infection and the dialysis patient.
Semin Dial.
2008;
21
440-446
-
236
Rawal B K, Parida S, Watkins R P et al.
Symptomatic reactivation of hepatitis B in pregnancy.
Lancet.
1991;
337
364
-
237
Yang Y B, Li X M, Shi Z J et al.
Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report.
World J Gastroenterol.
2004;
10
2305-2306
-
238
Jonas M M.
Hepatitis B and pregnancy: an underestimated issue.
Liver Int.
2009;
29 (Suppl 1)
133-139
-
239
Lin H H, Chen P J, Chen D S et al.
Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers.
J Med Virol.
1989;
29
1-6
-
240
ter Borg M J, Leemans W F, Man R A et al.
Exacerbation of chronic hepatitis B infection after delivery.
J Viral Hepat.
2008;
15
37-41
-
241
Lau W Y, Leung W T, Ho de S et al.
Hepatocellular carcinoma during pregnancy and its comparison with other pregnancy-associated malignancies.
Cancer.
1995;
75
2669-2676
-
242
Fwu C W, Chien Y C, Kirk G D et al.
Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.
J Natl Cancer Inst.
2009;
101
1019-1027
-
243
Yu M W, Chang H C, Chang S C et al.
Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk.
Hepatology.
2003;
38
1393-1400
-
244
Lao T T, Chan B C, Leung W C et al.
Maternal hepatitis B infection and gestational diabetes mellitus.
J Hepatol.
2007;
47
46-50
-
245
Wong S, Chan L Y, Yu V et al.
Hepatitis B carrier and perinatal outcome in singleton pregnancy.
Am J Perinatol.
1999;
16
485-488
-
246
Alexander J M, Ramus R, Jackson G et al.
Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers.
Infect Dis Obstet Gynecol.
1999;
7
283-286
-
247
Towers C V, Asrat T, Rumney P.
The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood.
Am J Obstet Gynecol.
2001;
184
1514-1518
; discussion 1518 – 1520
-
248
Han G, Zhao W, Cao M et al.
A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus (HBV) to the infants.
Hepatology.
2010;
52
427A-428A
-
249
Yang J, Zeng X M, Men Y L et al.
Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus – a systematic review.
Virol J.
2008;
5
100
-
250
Wang J, Zhu Q, Zhang X.
Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis.
Chin Med J.
2002;
115
1510-1512
-
251
Hill J B, Sheffield J S, Kim M J et al.
Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers.
Obstet Gynecol.
2002;
99
1049-1052
-
252
Johnson M A, Moore K H, Yuen G J et al.
Clinical pharmacokinetics of lamivudine.
Clin Pharmacokinet.
1999;
36
41-66
-
253
Burk R D, Hwang L Y, Ho G Y et al.
Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load.
J Infect Dis.
1994;
170
1418-1423
-
254
del Canho R, Grosheide P M, Mazel J A et al.
Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982 – 1992: protective efficacy and long-term immunogenicity.
Vaccine.
1997;
15
1624-1630
-
255
Wiseman E, Fraser M A, Holden S et al.
Perinatal transmission of hepatitis B virus: an Australian experience.
Med J Aust.
2009;
190
489-492
-
256
Zonneveld van M, Nunen A B, Niesters H G et al.
Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.
J Viral Hepat.
2003;
10
294-297
-
257
Xu W M, Cui Y T, Wang van L et al.
Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.
J Viral Hepat.
2009;
16
94-103
-
258
Kazim S N, Wakil S M, Khan L A et al.
Vertical transmission of hepatitis B virus despite maternal lamivudine therapy.
Lancet.
2002;
359
1488-1489
-
259
Li X M, Yang Y B, Hou H Y et al.
Interruption of HBV intrauterine transmission: a clinical study.
World J Gastroenterol.
2003;
9
1501-1503
-
260 Committee. A. P. R. S. .Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2009. 2009
-
261
Brown R S, Buti M, Goodwin D.
et al.
Hepatitis B Virus (HBV) Drugs in Pregnancy: Findings from the Antiretroviral Pregnancy Registry.
J Hepatol.
2009;
50
S4
-
262
Chotiyaputta W, Lok A S.
Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection.
J Viral Hepat.
2009;
16
91-93
-
263
Dhedin N, Douvin C, Kuentz M et al.
Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc.
Transplantation.
1998;
66
616-619
-
264
Iwai K, Tashima M, Itoh M et al.
Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient, reactivation of dormant virus during the immunosuppressive period.
Bone Marrow Transplant.
2000;
25
105-108
-
265
Kempinska A, Kwak E J, Angel J B.
Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature.
Clin Infect Dis.
2005;
41
1277-1282
-
266
Knoll A, Boehm S, Hahn J et al.
Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation.
Bone Marrow Transplant.
2004;
33
925-929
-
267
Romand F, Michallet M, Pichoud C et al.
[Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B].
Gastroenterol Clin Biol.
1999;
23
770-774
-
268
Lalazar G, Rund D, Shouval D.
Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
Br J Haematol.
2007;
136
699-712
-
269
Marcucci F, Mele A, Spada E et al.
High prevalence of hepatitis B virus infection in B-cell non-Hodgkin"s lymphoma.
Haematologica.
2006;
91
554-557
-
270
Palmore T N, Shah N L, Loomba R et al.
Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.
Clin Gastroenterol Hepatol.
2009;
7
1130-1137
-
271
Yeo W, Johnson P J.
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.
Hepatology.
2006;
43
209-220
-
272
Yeo W, Zee B, Zhong S et al.
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.
Br J Cancer.
2004;
90
1306-1311
-
273
Jang J W, Choi J Y, Bae S H et al.
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization.
Hepatology.
2006;
43
233-240
-
274
Park J W, Park K W, Cho S H et al.
Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study.
Am J Gastroenterol.
2005;
100
2194-2200
-
275
Floreani A, Boninsegna S, Lobello S et al.
Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal.
Gastroenterol Clin Biol.
2006;
30
307-309
-
276
Bae S H, Yoon S K, Choi J Y et al.
Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis.
J Gastroenterol Hepatol.
2005;
20
1527-1532
-
277
Chu C M, Liaw Y F.
Hepatitis B virus-related cirrhosis: natural history and treatment.
Semin Liver Dis.
2006;
26
142-152
-
278
Fontana R J, Hann H W, Perrillo R P et al.
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.
Gastroenterology.
2002;
123
719-727
-
279
Fontana R J, Keeffe E B, Carey W et al.
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.
Liver Transpl.
2002;
8
433-439
-
280
Kanwal F, Farid M, Martin P et al.
Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
Am J Gastroenterol.
2006;
101
2076-2089
-
281
Kapoor D, Guptan R C, Wakil S M et al.
Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.
J Hepatol.
2000;
33
308-312
-
282
Yao F Y, Terrault N A, Freise C et al.
Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
Hepatology.
2001;
34
411-416
-
283
Kim W R, Terrault N A, Pedersen R A et al.
Trends in waiting list registration for liver transplantation for viral hepatitis in the United States.
Gastroenterology.
2009;
137
1680-1686
-
284
Liaw Y F.
Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
Semin Liver Dis.
2005;
25 (Suppl 1)
40-47
-
285
Schiff E R, Lai C L, Hadziyannis S et al.
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
Hepatology.
2003;
38
1419-1427
-
286
Samuel D, Muller R, Alexander G et al.
Liver transplantation in European patients with the hepatitis B surface antigen.
N Engl J Med.
1993;
329
1842-1847
-
287
Anselmo D M, Ghobrial R M, Jung L C et al.
New era of liver transplantation for hepatitis B: a 17-year single-center experience.
Ann Surg.
2002;
235
611-619
; discussion 619 – 620
-
288
Benner K G, Lee R G, Keeffe E B et al.
Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation.
Gastroenterology.
1992;
103
1307-1312
-
289
Davies S E, Portmann B C, O"Grady J G et al.
Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis.
Hepatology.
1991;
13
150-157
-
290
Xiao S Y, Lu L, Wang H L.
Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis.
Int J Clin Exp Pathol.
2008;
1
396-402
-
291
Markowitz J S, Martin P, Conrad A J et al.
Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
Hepatology.
1998;
28
585-589
-
292
Marzano A, Salizzoni M, Debernardi-Venon W et al.
Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis.
J Hepatol.
2001;
34
903-910
-
293
Rosenau J, Bahr M J, Tillmann H L et al.
Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.
J Hepatol.
2001;
34
895-902
-
294
Steinmuller T, Seehofer D, Rayes N et al.
Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease.
Hepatology.
2002;
35
1528-1535
-
295
Katz L H, Paul M, Guy D G et al.
Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis.
Transpl Infect Dis.
2010;
12
292-308
-
296
Degertekin B, Han S H, Keeffe E B et al.
Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation.
Am J Transplant.
2010;
10
1823-1833
-
297
Gane E J, Angus P W, Strasser S et al.
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
Gastroenterology.
2007;
132
931-937
-
298
Shafique U, Watson C.
Current and evolving strategies against hepatitis B virus re-infection following liver transplantation.
European Gastroenterol Hepatol Review.
2010;
6
78-81
-
299
Rao W, Wu X, Xiu D.
Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis.
Transpl Int.
2009;
22
387-394
-
300
Zheng S, Chen Y, Liang T et al.
Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis.
Liver Transpl.
2006;
12
253-258
-
301
Saab S, Ham M Y, Stone M A et al.
Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
Liver Transpl.
2009;
15
413-420
-
302
Patterson S J, Angus P W.
Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
Curr Opin Organ Transplant.
2009;
14
225-230
-
303
Neff G W, Kemmer N, Kaiser T E et al.
Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
Dig Dis Sci.
2007;
52
2497-2500
-
304
Teperman L, Spivey J, Poordad F et al.
Emtricitabine tenofovir DF combination± HBIG post-orthotopic liver transplantation to prevent hepatitis b recurrence in patients with normal to moderate renal impairment: interim results.
J Hepatol.
2010;
52
S12-S13
-
305
Weber N K, Forman L M, Trotter J F.
HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients.
Dig Dis Sci.
2010;
55
505-509
-
306
Wong S N, Chu C J, Wai C T et al.
Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
Liver Transpl.
2007;
13
374-381
-
307
Buti M, Mas A, Prieto M et al.
Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence.
Transplantation.
2007;
84
650-654
-
308
Xi Z F, Xia Q, Zhang J J et al.
The role of entecavir in preventing hepatitis B recurrence after liver transplantation.
J Dig Dis.
2009;
10
321-327
-
309
Starkel P, Stoffel M, Lerut J et al.
Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
Liver Transpl.
2005;
11
1228-1234
-
310
Sanchez-Fueyo A, Rimola A, Grande L et al.
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
Hepatology.
2000;
31
496-501
-
311
Rosenau J, Hooman N, Rifai K et al.
Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response.
Transpl Int.
2006;
19
828-833
-
312
Bienzle U, Gunther M, Neuhaus R et al.
Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results.
Liver Transpl.
2002;
8
562-564
-
313
Beckebaum S, Sotiropoulos G C, Gerken G et al.
Hepatitis B and liver transplantation: 2008 update.
Rev Med Virol.
2009;
19
7-29
-
314
Ghany M G, Ayola B, Villamil F G et al.
Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.
Hepatology.
1998;
27
213-222
-
315
Limquiaco J L, Wong J, Wong V W et al.
Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study.
J Med Virol.
2009;
81
224-229
-
316
Protzer-Knolle U, Naumann U, Bartenschlager R et al.
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation.
Hepatology.
1998;
27
254-263
-
317
Terrault N, Roche B, Samuel D.
Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective.
Liver Transpl.
2005;
11
716-732
-
318
Lo C M, Liu C L, Lau G K et al.
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
Liver Transpl.
2005;
11
807-813
-
319
Perrillo R, Hann H W, Mutimer D et al.
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
Gastroenterology.
2004;
126
81-90
-
320
Schmutz G, Nelson M, Lutz T et al.
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
AIDS.
2006;
20
1951-1954
-
321
Ruiz R, Kunitake H, Wilkinson A H et al.
Long-term analysis of combined liver and kidney transplantation at a single center.
Arch Surg.
2006;
141
735-741
; discussion 741 – 742
-
322
Margreiter R, Kramar R, Huber C et al.
Combined liver and kidney transplantation.
Lancet.
1984;
1
1077-1078
-
323
Lang M, Neumann U, Kahl A et al.
Long-term outcome of 27 patients after combined liver-kidney transplantation.
Transplant Proc.
2001;
33
1440-1441
-
324
Poge U, Gerhardt T, Palmedo H et al.
MDRD equations for estimation of GFR in renal transplant recipients.
Am J Transplant.
2005;
5
1306-1311
-
325
Neumann U P, Lang M, Moldenhauer A et al.
Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation.
Transplantation.
2001;
71
1163-1168
-
326
Olausson M, Mjornstedt L, Norden G et al.
Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients.
Am J Transplant.
2007;
7
130-136
-
327
Fabrizi F, Martin P, Dixit V et al.
HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies.
Am J Transplant.
2005;
5
2913-2921
-
328
Gane E, Pilmore H.
Management of chronic viral hepatitis before and after renal transplantation.
Transplantation.
2002;
74
427-437
-
329
Hillis W D, Hillis A, Walker W G.
Hepatitis B surface antigenemia in renal transplant recipients. Increased mortality risk.
JAMA.
1979;
242
329-332
-
330
Pirson Y, Alexandre G P, Ypersele C.
Long-term effect of hbs antigenemia on patient survival after renal transplantation.
N Engl J Med.
1977;
296
194-196
-
331
Fornairon S, Pol S, Legendre C et al.
The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection.
Transplantation.
1996;
62
297-299
-
332
Mathurin P, Mouquet C, Poynard T et al.
Impact of hepatitis B and C virus on kidney transplantation outcome.
Hepatology.
1999;
29
257-263
-
333
Ahn H J, Kim M S, Kim Y S et al.
Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen.
J Med Virol.
2007;
79
1655-1663
-
334
Firpi R J, Nelson D R.
Viral hepatitis: manifestations and management strategy.
Hematology Am Soc Hematol Educ Program.
2006;
375-380
-
335
Giaccone L, Festuccia M, Marengo A et al.
Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Biol Blood Marrow Transplant.
2010;
16
809-817
-
336
Dai M S, Chao T Y.
Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?.
Breast Cancer Res Treat.
2005;
92
95-96
-
337
Hui C K, Cheung W W, Au W Y et al.
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
Gut.
2005;
54
1597-1603
-
338
Leaw S J, Yen C J, Huang W T et al.
Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
Ann Hematol.
2004;
83
270-275
-
339
Marusawa H, Chiba T.
How can we prevent viral reactivation in liver transplantation from donors with latent hepatitis B virus infection?.
J Gastroenterol.
2001;
36
212-213
-
340
Perez-Grande R, Gutierrez-Zufiaurre N, Munoz-Criado S et al.
Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: successful treatment with lamivudine and seroconversion.
Diagn Microbiol Infect Dis.
2009;
64
80-82
-
341
Vigano M, Vener C, Lampertico P et al.
Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT.
Bone Marrow Transplant.
2011;
46
125-131
-
342
Knoll A, Boehm S, Hahn J et al.
Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
J Viral Hepat.
2007;
14
478-483
-
343
Lau G K, Lok A S, Liang R H et al.
Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer.
Hepatology.
1997;
25
1497-1501
-
344
Lau G K, Suri D, Liang R et al.
Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen.
Gastroenterology.
2002;
122
614-624
-
345
Roche B, Samuel D, Gigou M et al.
De novo and apparent de novo hepatitis B virus infection after liver transplantation.
J Hepatol.
1997;
26
517-526
-
346
Rokuhara A, Tanaka E, Yagi S et al.
De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome.
J Med Virol.
2000;
62
471-478
-
347
Castells L, Vargas V, Rodriguez F et al.
Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Liver Transpl.
2002;
8
892-900
-
348
Segovia R, Sanchez-Fueyo A, Rimola A et al.
Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation.
Liver Transpl.
2001;
7
106-112
-
349
Perrillo R.
Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs.
Liver Transpl.
2009;
15
223-232
-
350
Cholongitas E, Papatheodoridis G V, Burroughs A K.
Liver grafts from anti-hepatitis B core positive donors: a systematic review.
J Hepatol.
2010;
52
272-279
-
351
Crespo J, Fabrega E, Casafont F et al.
Severe clinical course of de novo hepatitis B infection after liver transplantation.
Liver Transpl Surg.
1999;
5
175-183
-
352
Lin C C, Chen C L, Concejero A et al.
Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients.
Am J Transplant.
2007;
7
195-200
-
353
Su W J, Ho M C, Ni Y H et al.
High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
J Pediatr Gastroenterol Nutr.
2009;
48
203-208
-
354
Kim K H, Ahn S H, Chung H Y et al.
Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity.
J Gastroenterol Hepatol.
2004;
19
847-853
-
355
Dickson R C, Everhart J E, Lake J R et al.
Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Gastroenterology.
1997;
113
1668-1674
-
356
Douglas D D, Rakela J, Wright T L et al.
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient.
Liver Transpl Surg.
1997;
3
105-111
-
357
Manzarbeitia C, Reich D J, Ortiz J A et al.
Safe use of livers from donors with positive hepatitis B core antibody.
Liver Transpl.
2002;
8
556-561
-
358
Prieto M, Gomez M D, Berenguer M et al.
De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
Liver Transpl.
2001;
7
51-58
-
359
Avelino-Silva V I, D"Albuquerque L A, Bonazzi P R et al.
Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature.
Clin Transplant.
2010;
24
735-746
-
360
Prakoso E, Strasser S I, Koorey D J et al.
Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Clin Transplant.
2006;
20
369-373
-
361
Roque-Afonso A M, Feray C, Samuel D et al.
Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
Gut.
2002;
50
95-99
-
362
Uemoto S, Inomata Y, Sannomiya A et al.
Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors.
Transplant Proc.
1998;
30
134-135
-
363
Yu A S, Vierling J M, Colquhoun S D et al.
Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
Liver Transpl.
2001;
7
513-517
-
364
Pan J J, Oh S H, Soldevila-Pico C et al.
Low prevalence of HBV DNA in the liver allograft from anti-HBc-positive donors: a single-center experience.
Clin Transplant.
2011;
25
164-170
-
365
Yu L, Koepsell T, Manhart L et al.
Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor.
Liver Transpl.
2009;
15
1343-1350
-
366
De Feo T M, Poli F, Mozzi F et al.
Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study.
Transplant Proc.
2005;
37
1238-1239
-
367
Fabrizio F, Bunnapradist S, Martin P.
Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage.
J Nephrol.
2002;
15
605-613
-
368
Fytili P, Ciesek S, Manns M P et al.
Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients.
Transplantation.
2006;
81
808-809
-
369
Hartwig M G, Patel V, Palmer S M et al.
Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation.
Transplantation.
2005;
80
320-325
-
370
Dhillon G S, Levitt J, Mallidi H et al.
Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network For Organ Sharing Database.
Transplantation.
2009;
88
842-846
-
371
Veroux M, Puliatti C, Gagliano M et al.
Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and -negative recipients.
Transplant Proc.
2005;
37
2574-2575
-
372
Tenderich G, Zittermann A, Prohaska W et al.
Frequent detection of hepatitis B core antibodies in heart transplant recipients without preceding hepatitis B infection.
Transplant Proc.
2005;
37
4522-4524
-
373
Arslan M, Wiesner R H, Sievers C et al.
Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease.
Liver Transpl.
2001;
7
314-320
-
374
Chalasani N, Smallwood G, Halcomb J et al.
Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?.
Liver Transpl Surg.
1998;
4
128-132
-
375
Villeneuve E, Vincelette J, Villeneuve J P.
Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation.
Can J Gastroenterol.
2000;
14 (Suppl B)
59B-62B
-
376
Charest A F, McDougall J, Goldstein M B.
A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients.
Am J Kidney Dis.
2000;
36
976-982
-
377
Idilman R, De MN, Colantoni A et al.
The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C.
Am J Gastroenterol.
2002;
97
435-439
-
378
Bonazzi P R, Bacchella T, Freitas A C et al.
Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list.
Braz J Infect Dis.
2008;
12
306-309
-
379
Aziz A, Aziz S, Li D S et al.
Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease.
J Viral Hepat.
2006;
13
217-221
-
380
Walter J, Radun D, Claus H et al.
Hepatitis B and C risk factors in Germany – results of the national surveillance.
Gesundheitswesen.
2005;
67
441-447
-
381
Descos B, Scotto J, Fayol V et al.
Anti-HBc screening for the prevention of perinatal transmission of hepatitis B virus in France.
Infection.
1987;
15
434-439
-
382
Seaworth B, Drucker J, Starling J et al.
Hepatitis B vaccines in patients with chronic renal failure before dialysis.
J Infect Dis.
1988;
157
332-337
-
383
Brook G.
Prevention of viral hepatitis in HIV co-infection.
J Hepatol.
2006;
44
S104-S107
-
384
Kim H N, Harrington R D, Van Rompaey S E et al.
Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons.
Int J STD AIDS.
2008;
19
600-604
-
385
Landrum M L, Huppler Hullsiek K, Ganesan A et al.
Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD 4 count.
Vaccine.
2009;
27
4731-4738
-
386
Thierfelder W, Hellenbrand W, Meisel H et al.
Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998.
Eur J Epidemiol.
2001;
17
429-435
-
387
Coates T, Wilson R, Patrick G et al.
Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines.
Clin Ther.
2001;
23
392-403
-
388
Averhoff F, Mahoney F, Coleman P et al.
Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection.
Am J Prev Med.
1998;
15
1-8
-
389
del Canho R, Grosheide P M, Voogd M et al.
Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes.
J Med Virol.
1993;
41
30-34
-
390
Hadler S C, Francis D P, Maynard J E et al.
Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.
N Engl J Med.
1986;
315
209-214
-
391
Jilg W, Schmidt M, Deinhardt F.
Four-year experience with a recombinant hepatitis B vaccine.
Infection.
1989;
17
70-76
-
392
West D J, Calandra G B.
Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination.
Vaccine.
1996;
14
1019-1027
-
393
Wainwright R B, Bulkow L R, Parkinson A J et al.
Protection provided by hepatitis B vaccine in a Yupik Eskimo population – results of a 10-year study.
J Infect Dis.
1997;
175
674-677
-
394
European Consensus Group on Hepatitis B Immunity .
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity.
Lancet.
2000;
355
561-565
-
395
Banatvala J, Van Damme P, Oehen S.
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory.
Vaccine.
2000;
19
877-885
-
396
Bauer T, Jilg W.
Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination.
Vaccine.
2006;
24
572-577
-
397
Resti M, Azzari C, Mannelli F et al.
Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?.
Vaccine.
1997;
15
1338-1340
-
398
Watson B, West D J, Chilkatowsky A et al.
Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine.
Vaccine.
2001;
19
3164-3168
-
399
Zanetti A R, Mariano A, Romano L et al.
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
Lancet.
2005;
366
1379-1384
-
400
McMahon B J, Dentinger C M, Bruden D et al.
Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose.
J Infect Dis.
2009;
200
1390-1396
-
401
Poovorawan Y, Chongsrisawat V, Theamboonlers A et al.
Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers.
J Infect Dis.
2009;
200
33-38
-
402
Liao S S, Li R C, Li H et al.
Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children.
Vaccine.
1999;
17
2661-2666
-
403
Whittle H, Jaffar S, Wansbrough M et al.
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children.
BMJ.
2002;
325
569
-
404
Sande M A, Waight P A, Mendy van der M et al.
Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence.
PLoS One.
2007;
2
e753
-
405
Wismans P, Hattum van J, Stelling T et al.
Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination.
Hepatogastroenterology.
1988;
35
78-79
-
406
Jilg W, Schmidt M, Deinhardt F.
Inoculation failure following hepatitis B vaccination. The effect of additional vaccinations.
Dtsch Med Wochenschr.
1990;
115
1545-1548
-
407
Clemens R, Sanger R, Kruppenbacher J et al.
Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule – results of a post-marketing surveillance.
Vaccine.
1997;
15
349-352
-
408
Hasselhorn H M, Kralj N, Hofmann F et al.
Non- and low-response after preventive hepatitis B vaccination.
Gesundheitswesen.
1997;
59
321-328
-
409
Rendi-Wagner P, Wiedermann G, Stemberger H et al.
New vaccination strategies for low- and non-responders to hepatitis B vaccine.
Wien Klin Wochenschr.
2002;
114
175-180
-
410
Cardell K, Fryden A, Normann B.
Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise.
Scand J Infect Dis.
1999;
31
197-200
-
411
Carlsson T, Struve J, Sonnerborg A et al.
The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination.
Scand J Infect Dis.
1999;
31
93-95
-
412
Henderson E A, Louie T J, Ramotar K et al.
Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers.
Infect Control Hosp Epidemiol.
2000;
21
264-269
-
413
Rahman F, Dahmen A, Herzog-Hauff S et al.
Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.
Hepatology.
2000;
31
521-527
-
414
Sangare L, Manhart L, Zehrung D et al.
Intradermal hepatitis B vaccination: a systematic review and meta-analysis.
Vaccine.
2009;
27
1777-1786
-
415
Immunisation against hepatitis B.
Lancet.
1988;
1
875-876
-
416
Bruguera M, Rodicio J L, Alcazar J M et al.
Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients.
Vaccine.
1990;
8 (Suppl)
S47-S49
; discussion S 60-S62
-
417
Marangi A L, Giordano R, Montanaro A et al.
Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination.
Am J Kidney Dis.
1994;
23
537-542
-
418
Mitwalli A.
Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling.
Nephron.
1996;
73
417-420
-
419
Cruciani M, Mengoli C, Serpelloni G et al.
Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients.
Vaccine.
2009;
27
17-22
-
420
Rosman A S, Basu P, Galvin K et al.
Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial.
Am J Med.
1997;
103
217-222
-
421
Mettang T, Schenk U, Thomas S et al.
Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study.
Nephron.
1996;
72
192-196
-
422
Propst T, Propst A, Lhotta K et al.
Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination.
Am J Kidney Dis.
1998;
32
1041-1045
-
423
Barraclough K A, Wiggins K J, Hawley C M et al.
Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination.
Am J Kidney Dis.
2009;
54
95-103
-
424
Stevens C E, Alter H J, Taylor P E et al.
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy.
N Engl J Med.
1984;
311
496-501
-
425
Mast E E, Weinbaum C M, Fiore A E et al.
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults.
MMWR Recomm Rep.
2006;
55
1-33
; quiz CE 1–CE4
-
426
Lee C, Gong Y, Brok J et al.
Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers.
Cochrane Database Syst Rev.
2006;
CD004790
-
427
Mitsui T, Iwano K, Suzuki S et al.
Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls.
Hepatology.
1989;
10
324-327
-
428
Ayoola E A, Johnson A O.
Hepatitis B vaccine in pregnancy: immunogenicity, safety and transfer of antibodies to infants.
Int J Gynaecol Obstet.
1987;
25
297-301
-
429
Duclos P.
Safety of immunisation and adverse events following vaccination against hepatitis B.
Expert Opin Drug Saf.
2003;
2
225-231
-
430
Robert Koch-Institut .
Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen/Stand: Januar 2004.
Epidemiologisches Bulletin.
2004;
6
33-52
-
431
Geier M R, Geier D A.
Arthritic reactions following hepatitis B vaccination: an analysis of the vaccine adverse events reporting system (VAERS) data from 1990 through 1997.
Clin Exp Rheumatol.
2000;
18 (6)
789-790
-
432
Hernan M A, Jick S S, Olek M J et al.
Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study.
Neurology.
2004;
63
838-842
-
433
Girard M.
Autoimmune hazards of hepatitis B vaccine.
Autoimmun Rev.
2005;
4
96-100
-
434
Sadovnick A D, Scheifele D W.
School-based hepatitis B vaccination programme and adolescent multiple sclerosis.
Lancet.
2000;
355 (9203)
549-550
-
435
Monteyne P, Andre F E.
Is there a causal link between hepatitis B vaccination and multiple sclerosis?.
Vaccine.
2000;
18
1994-2001
-
436
Ascherio A, Zhang S M, Hernan M A et al.
Hepatitis B vaccination and the risk of multiple sclerosis.
N Engl J Med.
2001;
344
327-332
-
437
Confavreux C, Suissa S, Saddier P et al.
Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group.
N Engl J Med.
2001;
344
319-326
-
438
Schattner A.
Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines.
Vaccine.
2005;
23
3876-3886
-
439
Smedile A, Farci P, Verme G et al.
Influence of delta infection on severity of hepatitis B.
Lancet.
1982;
2
945-947
-
440
Caredda F, Rossi E, d"Arminio Monforte A et al.
Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome.
J Infect Dis.
1985;
151
925-928
-
441
Govindarajan S, Chin K P, Redeker A G et al.
Fulminant B viral hepatitis: role of delta agent.
Gastroenterology.
1984;
86
1417-1420
-
442
Hadler S C, De Monzon M, Ponzetto A et al.
Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela.
Ann Intern Med.
1984;
100
339-344
-
443
Le Gal F, Gault E, Ripault M P et al.
Eighth major clade for hepatitis delta virus.
Emerg Infect Dis.
2006;
12
1447-1450
-
444
Su C W, Huang Y H, Huo T I et al.
Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients.
Gastroenterology.
2006;
130
1625-1635
-
445
Huo T I, Wu J C, Lai C R et al.
Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection.
J Hepatol.
1996;
25
439-444
-
446
Liaw Y F, Chen Y C, Sheen I S et al.
Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection.
Gastroenterology.
2004;
126
1024-1029
-
447
Fattovich G, Boscaro S, Noventa F et al.
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.
J Infect Dis.
1987;
155
931-935
-
448
Fattovich G, Giustina G, Christensen E et al.
Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep).
Gut.
2000;
46
420-426
-
449
Rizzetto M, Verme G, Recchia S et al.
Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment.
Ann Intern Med.
1983;
98
437-441
-
450
Saracco G, Rosina F, Brunetto M R et al.
Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection.
J Hepatol.
1987;
5
274-281
-
451
Romeo R, Del Ninno E, Rumi M et al.
A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.
Gastroenterology.
2009;
136
1629-1638
-
452
Verme G, Brunetto M R, Oliveri F et al.
Role of hepatitis delta virus infection in hepatocellular carcinoma.
Dig Dis Sci.
1991;
36
1134-1136
-
453
Oyunsuren T, Kurbanov F, Tanaka Y et al.
High frequency of hepatocellular carcinoma in Mongolia, association with mono-, or co-infection with hepatitis C, B, and delta viruses.
J Med Virol.
2006;
78
1688-1695
-
454
Niro G A, Rosina F, Rizzetto M.
Treatment of hepatitis D.
J Viral Hepat.
2005;
12
2-9
-
455
Niro G A, Ciancio A, Gaeta G B et al.
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
Hepatology.
2006;
44
713-720
-
456
Erhardt A, Gerlich W, Starke C et al.
Treatment of chronic hepatitis delta with pegylated interferon alpha-2b.
Liver Int.
2006;
26
805-810
-
457
Gunsar F, Akarca U S, Ersoz G et al.
Two-year interferon therapy with or without ribavirin in chronic delta hepatitis.
Antivir Ther.
2005;
10
721-726
-
458
Lau D T, Kleiner D E, Park Y et al.
Resolution of chronic delta hepatitis after 12 years of interferon alpha therapy.
Gastroenterology.
1999;
117
1229-1233
-
459
Yurdaydin C, Bozkaya H, Onder F O et al.
Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon.
J Viral Hepat.
2008;
15
314-321
-
460
Farci P, Mandas A, Coiana A et al.
Treatment of chronic hepatitis D with interferon alpha-2a.
N Engl J Med.
1994;
330
88-94
-
461
Madejon A, Cotonat T, Bartolome J et al.
Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response.
Hepatology.
1994;
19
1331-1336
-
462
Rosina F, Pintus C, Meschievitz C et al.
A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study.
Hepatology.
1991;
13
1052-1056
-
463
Rosina F, Rizzetto M.
Treatment of chronic type D (delta) hepatitis with alpha interferon.
Semin Liver Dis.
1989;
9
264-266
-
464
Di Marco V, Giacchino R, Timitilli A et al.
Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.
J Viral Hepat.
1996;
3
123-128
-
465
Farci P, Roskams T, Chessa L et al.
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.
Gastroenterology.
2004;
126
1740-1749
-
466
Niro G A, Ciancio A, Tillman H L et al.
Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study.
Aliment Pharmacol Ther.
2005;
22
227-232
-
467
Yurdaydin C, Bozkaya H, Gurel S et al.
Famciclovir treatment of chronic delta hepatitis.
J Hepatol.
2002;
37
266-271
-
468
Lau D T, Doo E, Park Y et al.
Lamivudine for chronic delta hepatitis.
Hepatology.
1999;
30
546-549
-
469
Garripoli A, Di Marco V, Cozzolongo R et al.
Ribavirin treatment for chronic hepatitis D: a pilot study.
Liver.
1994;
14
154-157
-
470
Wolters L M, Nunen A B, Honkoop van P et al.
Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus.
J Viral Hepat.
2000;
7
428-434
-
471
Sheldon J, Ramos B, Toro C et al.
Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?.
Antivir Ther.
2008;
13
97-102
-
472
Lucey M R, Graham D M, Martin P et al.
Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation.
Gut.
1992;
33
1390-1396
-
473
Rizzetto M, Macagno S, Chiaberge E et al.
Liver transplantation in hepatitis delta virus disease.
Lancet.
1987;
2
469-471
-
474
Samuel D, Zignego A L, Reynes M et al.
Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.
Hepatology.
1995;
21
333-339
-
475
Rifai K, Wedemeyer H, Rosenau J et al.
Longer survival of liver transplant recipients with hepatitis virus coinfections.
Clin Transplant.
2007;
21
258-264
-
476
Sagnelli E, Coppola N, Pisaturo M et al.
HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV.
Hepatology.
2009;
49
1090-1097
-
477
Sagnelli E, Coppola N, Scolastico C et al.
Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis.
Hepatology.
2000;
32
1106-1110
-
478
Zarski J P, Bohn B, Bastie A et al.
Characteristics of patients with dual infection by hepatitis B and C viruses.
J Hepatol.
1998;
28
27-33
-
479
Amin J, Law M G, Bartlett M et al.
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study.
Lancet.
2006;
368
938-945
-
480
Di Marco V, Lo Iacono O, Camma C et al.
The long-term course of chronic hepatitis B.
Hepatology.
1999;
30
257-264
-
481
Chen Y C, Sheen I S, Chu C M et al.
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.
Gastroenterology.
2002;
123
1084-1089
-
482
Ilan Y, Ashur Y, Tur-Kaspa R et al.
Chronic hepatitis C virus infection with exposure to hepatitis B virus.
Isr J Med Sci.
1994;
30
259-263
-
483
Benvegnu L, Fattovich G, Noventa F et al.
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study.
Cancer.
1994;
74
2442-2448
-
484
Donato F, Boffetta P, Puoti M.
A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma.
Int J Cancer.
1998;
75
347-354
-
485
Shi J, Zhu L, Liu S et al.
A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China.
Br J Cancer.
2005;
92
607-612
-
486
Cacciola I, Pollicino T, Squadrito G et al.
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
N Engl J Med.
1999;
341
22-26
-
487
Hui C K, Lau E, Wu H et al.
Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection.
J Clin Virol.
2006;
35
185-192
-
488
Raimondo G, Navarra G, Mondello S et al.
Occult hepatitis B virus in liver tissue of individuals without hepatic disease.
J Hepatol.
2008;
48
743-746
-
489
Chen L W, Chien R N, Yen C L et al.
Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
J Gastroenterol Hepatol.
2010;
25
259-263
-
490
Levast M, Larrat S, Thelu M A et al.
Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
J Med Virol.
2010;
82
747-754
-
491
Fukuda R, Ishimura N, Niigaki M et al.
Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance.
J Med Virol.
1999;
58
201-207
-
492
Sagnelli E, Coppola N, Scolastico C et al.
HCV genotype and „silent” HBV coinfection: two main risk factors for a more severe liver disease.
J Med Virol.
2001;
64
350-355
-
493
Liu C J, Chen P J, Lai M Y et al.
Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients.
Hepatology.
2003;
37
568-576
-
494
Chuang W L, Dai C Y, Chang W Y et al.
Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Antivir Ther.
2005;
10
125-133
-
495
Hung C H, Lee C M, Lu S N et al.
Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection.
J Gastroenterol Hepatol.
2005;
20
727-732
-
496
Potthoff A, Wedemeyer H, Boecher W O et al.
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon alpha-2b and ribavirin in patients with HBV/HCV co-infection.
J Hepatol.
2008;
49
688-694
-
497
Liu C J, Chuang W L, Lee C M et al.
Peginterferon alpha-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Gastroenterology.
2009;
136
496-504.e3
-
498
Potthoff A, Berg T, Wedemeyer H.
Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.
Scand J Gastroenterol.
2009;
44
1487-1490
-
499
Liaw Y F, Chien R N, Lin S M et al.
Response of patients with dual hepatitis B virus and C virus infection to interferon therapy.
J Interferon Cytokine Res.
1997;
17
449-452
-
500
Bodsworth N J, Cooper D A, Donovan B.
The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state.
J Infect Dis.
1991;
163
1138-1140
-
501
Hadler S C, Judson F N, O"Malley P M et al.
Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection.
J Infect Dis.
1991;
163
454-459
-
502
Chun H M, Fieberg A M, Hullsiek K H et al.
Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.
Clin Infect Dis.
2010;
50
426-436
-
503
Nikolopoulos G K, Paraskevis D, Hatzitheodorou E et al.
Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis.
Clin Infect Dis.
2009;
48
1763-1771
-
504
Larsen C, Pialoux G, Salmon D et al.
Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004.
Euro Surveill.
2008;
13
pii: 18888
-
505
Omland L H, Weis N, Skinhoj P et al.
Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
HIV Med.
2008;
9
300-306
-
506
Konopnicki D, Mocroft A, Wit de S et al.
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
AIDS.
2005;
19
593-601
-
507
Soriano V, Mocroft A, Peters L et al.
Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.
J Antimicrob Chemother.
2010;
65
548-555
-
508
Bodsworth N, Donovan B, Nightingale B N.
The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.
J Infect Dis.
1989;
160
577-582
-
509
Thio C L, Seaberg E C, Skolasky R J et al.
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).
Lancet.
2002;
360
1921-1926
-
510
Monforte A, Abrams D, Pradier C et al.
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
AIDS.
2008;
22
2143-2153
-
511
Weber R, Sabin C A, Friis-Moller N et al.
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
Arch Intern Med.
2006;
166
1632-1641
-
512
Clifford G M, Rickenbach M, Polesel J et al.
Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma.
AIDS.
2008;
22
2135-2141
-
513
Miailhes P, Trabaud M A, Pradat P et al.
Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Clin Infect Dis.
2007;
45
624-632
-
514
Nunez M, Ramos B, Diaz-Pollan B et al.
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
AIDS Res Hum Retroviruses.
2006;
22
842-848
-
515
Landrum M L, Fieberg A M, Chun H M et al.
The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults.
PLoS One.
2010;
5
e8687
-
516
Matthews G V, Cooper D A, Dore G J.
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Antivir Ther.
2007;
12
119-122
-
517
Osborn M K, Guest J L, Rimland D.
Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease.
HIV Med.
2007;
8
271-279
-
518
Puoti M, Torti C, Bruno R et al.
Natural history of chronic hepatitis B in co-infected patients.
J Hepatol.
2006;
44
S65-S70
-
519
Rockstroh J K.
Influence of viral hepatitis on HIV infection.
J Hepatol.
2006;
44
S25-S27
-
520
Hoffmann C J, Seaberg E C, Young S et al.
Hepatitis B and long-term HIV outcomes in coinfected HAART recipients.
AIDS.
2009;
23
1881-1889
-
521
Martinez E, Blanco J L, Arnaiz J A et al.
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
AIDS.
2001;
15
1261-1268
-
522
Spengler U, Lichterfeld M, Rockstroh J K.
Antiretroviral drug toxicity – a challenge for the hepatologist?.
J Hepatol.
2002;
36
283-294
-
523
Wit F W, Weverling G J, Weel J et al.
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
J Infect Dis.
2002;
186
23-31
-
524
Cicconi P, Cozzi-Lepri A, Phillips A et al.
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?.
AIDS.
2007;
21
599-606
-
525
Rachlis A, Clotet B, Baxter J et al.
Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
HIV Clin Trials.
2007;
8
213-220
-
526
Torti C, Lapadula G, Uccelli M C et al.
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients.
Int J Antimicrob Agents.
2007;
29
185-190
-
527
Palacios R, Vergara S, Rivero A et al.
Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.
HIV Clin Trials.
2006;
7
319-323
-
528
Mocroft A, Soriano V, Rockstroh J et al.
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?.
AIDS.
2005;
19
2117-2125
-
529
Walker U A, Bauerle J, Laguno M et al.
Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
Hepatology.
2004;
39
311-317
-
530
Chauvel O, Lacombe K, Bonnard P et al.
Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy.
Antivir Ther.
2007;
12
1115-1126
-
531
Guitton E, Montastruc J L, Lapeyre-Mestre M.
Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients.
Eur J Clin Pharmacol.
2006;
62
243-249
-
532
Pineda J A, Santos J, Rivero A et al.
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
J Antimicrob Chemother.
2008;
61
925-932
-
533
Crane M, Oliver B, Matthews G et al.
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.
J Infect Dis.
2009;
199
974-981
-
534
Dore G J, Soriano V, Rockstroh J et al.
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
AIDS.
2010;
24
857-865
-
535
Tedaldi E, Peters L, Neuhaus J et al.
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.
Clin Infect Dis.
2008;
47
1468-1475
-
536
Castellares C, Barreiro P, Martin-Carbonero L et al.
Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome.
J Viral Hepat.
2008;
15
165-172
-
537
Murillas J, Rimola A, Laguno M et al.
The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
Liver Transpl.
2009;
15
1133-1141
-
538
Rockstroh J K, Bhagani S, Benhamou Y et al.
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
HIV Med.
2008;
9
82-88
-
539
McDonald J A, Harris S, Waters J A et al.
Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display.
J Hepatol.
1987;
4
337-342
-
540
Wong D K, Yim C, Naylor C D et al.
Interferon alpha treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population.
Gastroenterology.
1995;
108
165-171
-
541
Chen D K, Yim C, O"Rourke K et al.
Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population.
J Hepatol.
1999;
30
557-563
-
542
Martino di V, Lunel F, Cadranel J F et al.
Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B.
J Viral Hepat.
1996;
3
253-260
-
543
Di Martino V, Thevenot T, Colin J F et al.
Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.
Gastroenterology.
2002;
123
1812-1822
-
544
Marcellin P, Boyer N, Colin J F et al.
Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine.
Gut.
1993;
34
S106
-
545
Soriano V, Puoti M, Bonacini M et al.
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
AIDS.
2005;
19
221-240
-
546
Di Martino V, Thevenot T, Boyer N et al.
Serum alanine transaminase level is a good predictor of response to interferon alpha therapy for chronic hepatitis B in human immunodeficiency virus-infected patients.
Hepatology.
2000;
31
1030-1031
-
547
Wong D K, Cheung A M, O"Rourke K et al.
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.
Ann Intern Med.
1993;
119
312-323
-
548
Benhamou Y, Bochet M, Thibault V et al.
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
Hepatology.
1999;
30
1302-1306
-
549
Dore G J, Cooper D A, Barrett C et al.
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
J Infect Dis.
1999;
180
607-613
-
550
Hoff J, Bani-Sadr F, Gassin M et al.
Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
Clin Infect Dis.
2001;
32
963-969
-
551
Johnson R M, Ristig M B, Overton E T et al.
Safety and tolerability of sequential pegylated IFN-alpha-2a and tenofovir for hepatitis B infection in HIV(+ ) individuals.
HIV Clin Trials.
2007;
8
173-181
-
552
Puoti M, Cozzi-Lepri A, Paraninfo G et al.
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.
Antivir Ther.
2006;
11
567-574
-
553
Matthews G V, Bartholomeusz A, Locarnini S et al.
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
AIDS.
2006;
20
863-870
-
554
Kamili S, Sozzi V, Thompson G et al.
Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.
Hepatology.
2009;
49
1483-1491
-
555
Sheldon J, Ramos B, Garcia-Samaniego J et al.
Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.
J Acquir Immune Defic Syndr.
2007;
46
279-282
-
556
Delaugerre C, Marcelin A G, Thibault V et al.
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Antimicrob Agents Chemother.
2002;
46
1586-1588
-
557
Sheldon J A, Corral A, Rodes B et al.
Risk of selecting K 65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.
AIDS.
2005;
19
2036-2038
-
558
Sheldon J, Camino N, Rodes B et al.
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Antivir Ther.
2005;
10
727-734
-
559
Audsley J, Arrifin N, Yuen L K et al.
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
HIV Med.
2009;
10
229-235
-
560
Tan J, Degertekin B, Wong S N et al.
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
J Hepatol.
2008;
48
391-398
-
561
Amini-Bavil-Olyaee S, Herbers U, Sheldon J et al.
The rtA194 T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
Hepatology.
2009;
49
1158-1165
-
562
Amini-Bavil-Olyaee S, Vucur M, Luedde T et al.
Differential impact of immune escape mutations G 145R and P 120 T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
J Virol.
2010;
84
1026-1033
-
563
Lin P F, Nowicka-Sans B, Terry B et al.
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
Antimicrob Agents Chemother.
2008;
52
1759-1767
-
564
McMahon M A, Jilek B L, Brennan T P et al.
The HBV drug entecavir – effects on HIV-1 replication and resistance.
N Engl J Med.
2007;
356
2614-2621
-
565
Sasadeusz J, Audsley J, Mijch A et al.
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.
AIDS.
2008;
22
947-955
-
566
Lin K, Karwowska S, Lam E et al.
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
Antimicrob Agents Chemother.
2010;
54
2670-2673
-
567
Low E, Cox A, Atkins M et al.
Telbivudine has activity against HIV-1.
AIDS.
2009;
23
546-547
-
568
Milazzo L, Caramma I, Lai A et al.
Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy.
Antivir Ther.
2009;
14
869-872
-
569
Bellini C, Keiser O, Chave J P et al.
Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study.
HIV Med.
2009;
10
12-18
-
570
Lim S G, Krastev Z, Ng T M et al.
Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.
Antimicrob Agents Chemother.
2006;
50
1642-1648
-
571
Matthews G V, Avihingsanon A, Lewin S R et al.
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand.
Hepatology.
2008;
48
1062-1069
-
572
Matthews G V, Seaberg E, Dore G J et al.
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals.
AIDS.
2009;
23
1707-1715
-
573
Pineda J A, Romero-Gomez M, Diaz-Garcia F et al.
HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.
Hepatology.
2005;
41
779-789
-
574
Ragni M V, Eghtesad B, Schlesinger K W et al.
Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease.
Liver Transpl.
2005;
11
1425-1430
-
575
Neff G W, Bonham A, Tzakis A G et al.
Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease.
Liver Transpl.
2003;
9
239-247
-
576
Ragni M V, Belle S H, Im K et al.
Survival of human immunodeficiency virus-infected liver transplant recipients.
J Infect Dis.
2003;
188
1412-1420
-
577
Mindikoglu A L, Regev A, Magder L S.
Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database.
Transplantation.
2008;
85
359-368
-
578
Coffin C S, Stock P G, Dove L M et al.
Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients.
Am J Transplant.
2010;
10
1268-1275
-
579
Arribas J R, Gonzalez-Garcia J J, Lorenzo A et al.
Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain.
AIDS.
2005;
19
1361-1365
-
580
Buti M, Jardi R, Allende H et al.
Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections?.
J Med Virol.
1996;
49
66-69
-
581
Sheng W H, Hung C C, Kao J H et al.
Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
Clin Infect Dis.
2007;
44
988-995
-
582
Mathurin P, Thibault V, Kadidja K et al.
Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections.
J Viral Hepat.
2000;
7
15-22
-
583
Weltman M D, Brotodihardjo A, Crewe E B et al.
Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.
J Viral Hepat.
1995;
2
39-45
-
584
Raimondo G, Brunetto M R, Pontisso P et al.
Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients.
Hepatology.
2006;
43
100-107
-
585
Lacombe K, Boyd A, Desvarieux M et al.
Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus.
AIDS.
2007;
21
2546-2549
-
586
Pontisso P, Ruvoletto M G, Fattovich G et al.
Clinical and virological profiles in patients with multiple hepatitis virus infections.
Gastroenterology.
1993;
105
1529-1533
-
587
Liaw Y F, Tsai S L, Sheen I S et al.
Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers.
Am J Gastroenterol.
1998;
93
354-359
-
588
Jardi R, Rodriguez F, Buti M et al.
Role of hepatitis B, C, D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference.
Hepatology.
2001;
34
404-410
-
589
Heidrich B, Deterding K, Tillmann H L et al.
Virological and clinical characteristics of delta hepatitis in Central Europe.
J Viral Hepat.
2009;
16
883-894
-
590
Antonucci G, Vairo F, Iacomi F et al.
Role of hepatitis B virus, hepatitis D virus and other determinants on suppression of hepatitis C viraemia in HIV infected patients with chronic HCV infection: a longitudinal evaluation.
Scand J Infect Dis.
2008;
40
928-934
-
591
Maida I, Rios M J, Perez-Saleme L et al.
Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era.
AIDS Res Hum Retroviruses.
2008;
24
679-683
-
592
Morsica G, Bagaglio S, Cicconi P et al.
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.
J Acquir Immune Defic Syndr.
2009;
51
574-581
-
593
Boyd A, Lacombe K, Miailhes P et al.
Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus.
J Viral Hepat.
2010;
17
65-76
-
594
Soriano V, Barreiro P, Martin-Carbonero L et al.
Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.
J Infect Dis.
2007;
195
1181-1183
-
595
Sarrazin C, Berg T, Ross R S et al.
Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection.
Z Gastroenterol.
2010;
48
289-351
-
596 Thomas H C, Lemon S, Zuckerman A J. Viral Hepatitis. Malden, MA Blackwell Publishing; 2005
-
597
Ranger-Rogez S, Denis F.
Hepatitis B mother-to-child transmission.
Expert Rev Anti Infect Ther.
2004;
2
133-145
-
598
Tabor E.
Infections by hepatitis B surface antigen gene mutants in Europe and North America.
J Med Virol.
2006;
78 (Suppl 1)
S43-S47
-
599
Gigliotti A R, Fioredda F, Giacchino R.
Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation.
J Pediatr Hematol Oncol.
2003;
25
184-192
-
600
Lackner H, Moser A, Benesch M et al.
Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy.
J Clin Virol.
2002;
25 (Suppl 3)
S73-S79
-
601
Kelly D.
Viral hepatitis in children.
Adv Exp Med Biol.
2004;
549
83-90
-
602
Bortolotti F, Guido M, Bartolacci S et al.
Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study.
Hepatology.
2006;
43
556-562
-
603
Lok A S, Lai C L.
A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children.
Hepatology.
1988;
8
1130-1133
-
604
Wintermeyer P, Gerner P, Gehring S et al.
Prevalence of hepatitis B virus precore stop codon mutations in chronically infected children.
World J Gastroenterol.
2006;
12
2235-2238
-
605
Deutsch J, Wirth S.
Konsens über die Behandlung der chronischen Hepatitis B im Kindesalter.
Monatsschr Kinderheilkd.
2002;
150
625-629
-
606
Laubscher B, Gehri M, Roulet M et al.
Survival of infantile fulminant hepatitis B and treatment with Lamivudine.
J Pediatr Gastroenterol Nutr.
2005;
40
518-520
-
607
Hartman C, Berkowitz D, Eshach-Adiv O et al.
Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon.
J Pediatr Gastroenterol Nutr.
2006;
43
494-498
-
608
Bortolotti F, Jara P, Barbera C et al.
Long term effect of alpha interferon in children with chronic hepatitis B.
Gut.
2000;
46
715-718
-
609
Jonas M M, Mizerski J, Badia I B et al.
Clinical trial of lamivudine in children with chronic hepatitis B.
N Engl J Med.
2002;
346
1706-1713
-
610
Hom X, Little N R, Gardner S D et al.
Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection.
Pediatr Infect Dis J.
2004;
23
441-445
-
611
Vo Thi Diem H, Bourgois A, Bontems P et al.
Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls.
J Pediatr Gastroenterol Nutr.
2005;
40
141-145
-
612
Sokal E.
Drug treatment of pediatric chronic hepatitis B.
Paediatr Drugs.
2002;
4
361-369
-
613
Bortolotti F.
Treatment of chronic hepatitis B in children.
J Hepatol.
2003;
39 (Suppl 1)
S200-S205
-
614
Dikici B, Bosnak M, Bosnak V et al.
Combination therapy for children with chronic hepatitis B virus infection.
J Gastroenterol Hepatol.
2002;
17
1087-1091
-
615
Dikici B, Ozgenc F, Kalayci A G et al.
Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study.
J Gastroenterol Hepatol.
2004;
19
127-133
-
616
Maria Elzbieta S L, Marek L D.
Histological outcome of chronic hepatitis B in children treated with interferon alpha.
World J Gastroenterol.
2005;
11
7179-7182
-
617
Saltik-Temizel I N, Kocak N, Demir H.
Interferon-alpha and lamivudine combination therapy of children with chronic hepatitis b infection who were interferon-alpha nonresponders.
Pediatr Infect Dis J.
2004;
23
466-468
-
618
Zuccotti G V, Cucchi C, Gracchi V et al.
A 1-year trial of lamivudine for chronic hepatitis B in children.
J Int Med Res.
2002;
30
200-202
-
619
Ni Y H, Huang F C, Wu T C et al.
Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients.
Pediatr Int.
2005;
47
372-377
-
620
D"Antiga L, Aw M, Atkins M et al.
Combined lamivudine/interferon-alpha treatment in „immunotolerant” children perinatally infected with hepatitis B: a pilot study.
J Pediatr.
2006;
148
228-233
-
621
Ozgenc F, Arikan C, Sertoz R Y et al.
Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Antivir Ther.
2004;
9
729-732
-
622
Saltik-Temizel I N, Kocak N, Demir H.
Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection.
J Clin Gastroenterol.
2005;
39
68-70
-
623
Gregorio G V, Jara P, Hierro L et al.
Lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial.
Hepatology.
1996;
23
700-707
-
624
Sokal E M, Kelly D A, Mizerski J et al.
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.
Hepatology.
2006;
43
225-232
-
625
Lee C, Gong Y, Brok J et al.
Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis.
BMJ.
2006;
332
328-336
-
626
Marion S A, Tomm Pastore M, Pi D W et al.
Long-term follow-up of hepatitis B vaccine in infants of carrier mothers.
Am J Epidemiol.
1994;
140
734-746
-
627
Beasley R P, Stevens C E, Shiao I S et al.
Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B.
Lancet.
1975;
2
740-741
-
628
Martino de M, Appendino C, Resti M et al.
Should hepatitis B surface antigen positive mothers breast feed?.
Arch Dis Child.
1985;
60
972-974
-
629
Wang J S, Zhu Q R, Wang X H.
Breastfeeding does not pose any additional risk of immunoprophylaxis failure on infants of HBV carrier mothers.
Int J Clin Pract.
2003;
57
100-102
-
630
Bracciale L, Fabbiani M, Sansoni A et al.
Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study.
Infection.
2009;
37
340-343
-
631
Heininger U, Vaudaux B, Nidecker M et al.
Evaluation of the compliance with recommended procedures in newborns exposed to HBsAg-positive mothers: a multicenter collaborative study.
Pediatr Infect Dis J.
2010;
29
248-250
17
1 Minderheitenveto: Einige Virologen forderten darüber hinaus gehend, dass in jedem Fall vor Beendigung der Therapie eine negative HBV-DNA vorliegen soll (entspricht Empfehlungsgrad A).
Prof. Dr. med. Michael P. Manns
Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30623 Hannover
Phone: ++ 49/5 11/5 32 33 05
Fax: ++ 49/5 11/5 32 48 96
Email: manns.michael@mh-hannover.de
